肠肝轴:在肝脏疾病中的分子机制和治疗向
Liang Ma1, He Wang2, Qiuyu Jin3
1First Clinical Medical College, Heilongjiang University of Chinese Medicine, Harbin, 150040, People's Republic of China.
International journal of general medicine
|December 22, 2025
概括
肠道微生物群通过复杂的信号传递影响肝脏健康. 调节肠道微生物组显示出治疗肝脏疾病的前景,传统中医提供独特的治疗途径.
科学领域:
- 微生物组研究的研究.
- 胃肠病学 胃肠病学
- 肝病学 肝病学是一种肝病学.
背景情况:
- 肠道微生物群,一个复杂的生物网络,影响系统生理学.
- 微生物多样性与肠道健康有关,但其在整体平衡中的作用尚未完全理解.
- 肠肝轴是双向通信通道,对于保持健康至关重要.
研究的目的:
- 审查当前关于肠肝轴的证据.
- 阐明肠道微生物群在肝脏健康中的生物学途径和治疗应用.
- 突出传统中医药 (TCM) 在调节肠肝轴上的作用.
主要方法:
- 临床试验,随机对照试验 (RCT),系统审查和元分析的系统审查.
- 对肠肝沟通的分子机制的分析.
- 肠道微生物群和代谢物在肝病病原和治疗中的分类.
主要成果:
- 肠道微生物群调节已证实有有益的生理效应.
- 机械洞察力主要来自动物模型,需要更多的临床翻译.
- 有证据支持针对肝脏疾病的微生物向策略.
结论:
- 肠肝轴是治疗干预的关键目标.
- 针对微生物组的策略显示出肝脏疾病的显著临床价值.
- 需要进行进一步的研究,包括长期队列研究,以充分转化研究结果.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
445
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
445
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
200
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
200
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
169
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
169
Targets for Drug Action: Overview
9.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.9K
Hepatic Drug Clearance: Role of Transporters
281
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
281
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
445
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
445


